6HV1 Stock Overview
A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Rezolute, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.20 |
| 52 Week High | US$5.05 |
| 52 Week Low | US$4.20 |
| Beta | 1.08 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -8.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6HV1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.9% | -1.2% | -1.4% |
| 1Y | n/a | -13.2% | 8.0% |
Return vs Industry: Insufficient data to determine how 6HV1 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 6HV1 performed against the German Market.
Price Volatility
| 6HV1 volatility | |
|---|---|
| 6HV1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 6HV1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 6HV1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 18 | Nevan Elam | www.rezolutebio.com |
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. The company’s lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema.
Rezolute, Inc. Fundamentals Summary
| 6HV1 fundamental statistics | |
|---|---|
| Market cap | €248.24m |
| Earnings (TTM) | -€66.88m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.4x
P/E RatioIs 6HV1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6HV1 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$69.31m |
| Earnings | -US$69.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6HV1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 18:08 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rezolute, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Edward Nash | Canaccord Genuity |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |